Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind placebo-controlled ascending-dose study of JTK-652 in chronic hepatitis C
NL-OMON31911Phase 1Active, not recruiting
- Sponsor
- Japan Tobacco
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatitis C virus infection comparing JTK-652 ascending-dose arm with Placebo arm (2 arms). Primary endpoint: Safety and tolerability. Started Jan 2008; status: active, not recruiting.
02
Drugs
JTK-652
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON31911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31911.